A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 9, 2021

Primary Completion Date

April 7, 2022

Study Completion Date

May 31, 2022

Conditions

Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD RiskElevated CholesterolHealthy Volunteers

Interventions

DRUG

NNC0385-0434

All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days

Trial Locations (1)

Novo Nordisk Investigational Site, Berlin